What does ARSPHARMA do?

ARSPHARMA is an architecture firm in Malle. Private Limited, started on 12 October 2012, 1 establishment.

What is the address of ARSPHARMA?

The registered office of ARSPHARMA is located at Antwerpsesteenweg 281A, 2390 Malle.

Is ARSPHARMA still active?

Yes. According to the CBE (30 September 2026) ARSPHARMA is active, legal situation “Normale toestand”, started on 12 October 2012.

Is ARSPHARMA registered on Peppol?

Yes, ARSPHARMA is registered on the Peppol network with ID 0208:0849745437.

What is the enterprise number of ARSPHARMA?

The enterprise number of ARSPHARMA is BE0849745437.

When was ARSPHARMA founded?

ARSPHARMA was founded on 12 October 2012.

The shares are held by REMEDIA (100%) and MDC-INTERIEUR (100%). It owns 100% of Apotheek Management op Maat BV itself.

Is ARSPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 October 2012; 5 annual accounts filed, latest fiscal year 2025.

How much profit did ARSPHARMA make in 2025?

ARSPHARMA posted a profit after taxes of € 28,113 in financial year 2025.

What is the revenue of ARSPHARMA?

As a small company, ARSPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 101,856.

How many employees does ARSPHARMA have?

According to the 2025 annual accounts, ARSPHARMA has 0.5 full-time equivalents (FTE).

Does ARSPHARMA have a website?

Yes, ARSPHARMA has a website at arspharma.be.

ARSPHARMA (Private Limited) - Malle - BE0849745437

Dossier ARSPHARMA, printed on 30 September 2026 from databakkes.be/en/0849745437/arspharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ARSPHARMA from Malle, company number BE0849745437, closed financial year 2025 with a result of € 28,113 after tax. For that financial year ARSPHARMA recorded a gross margin of € 101,856 and equity of € 197,851. Compared with financial year 2024, the result moved from € 12,475 to € 28,113. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 29, 2026.

What it is worth Growing

€ 197,851

▲ 17% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 28,113

▲ 125% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 108,459

▼ 9% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 191,551.

People and assets in 2025

Full-time equivalents

0.5

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 22,890

▼ 20% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,349

▼ 21% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 142,106

▼ 38% vs 2024

€ 12,106 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 459,241

▲ 72% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 22,192

▼ 23% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 40,521 Gross margin 2022: € 40,521 First fiscal year in the series	€ 92,408 Gross margin 2023: € 92,408 ▲ 128% vs 2022 (€ 40,521) Favourable step	€ 69,943 Gross margin 2024: € 69,943 ▼ 24% vs 2023 (€ 92,408) Unfavourable step	€ 101,856 Gross margin 2025: € 101,856 ▲ 46% vs 2024 (€ 69,943) Favourable step	▲ 46%
Profit after taxes	€ -1,118 Profit after taxes 2022: € -1,118 First fiscal year in the series	€ 32,250 Profit after taxes 2023: € 32,250 ▲ € 33,368 vs 2022 (€ -1,118) Favourable step	€ 12,475 Profit after taxes 2024: € 12,475 ▼ 61% vs 2023 (€ 32,250) Unfavourable step	€ 28,113 Profit after taxes 2025: € 28,113 ▲ 125% vs 2024 (€ 12,475) Favourable step	▲ 125%
Equity	€ 125,013 Equity 2022: € 125,013 First fiscal year in the series	€ 157,263 Equity 2023: € 157,263 ▲ 26% vs 2022 (€ 125,013) Favourable step	€ 169,738 Equity 2024: € 169,738 ▲ 8% vs 2023 (€ 157,263) Favourable step	€ 197,851 Equity 2025: € 197,851 ▲ 17% vs 2024 (€ 169,738) Favourable step	▲ 17%
Total debts	€ 650,249 Total debts 2022: € 650,249 First fiscal year in the series	€ 690,433 Total debts 2023: € 690,433 ▲ 6% vs 2022 (€ 650,249) Unfavourable step	€ 534,137 Total debts 2024: € 534,137 ▼ 23% vs 2023 (€ 690,433) Favourable step	€ 641,295 Total debts 2025: € 641,295 ▲ 20% vs 2024 (€ 534,137) Unfavourable step	▲ 20%
Cash	€ 153,391 Cash 2022: € 153,391 First fiscal year in the series	€ 187,686 Cash 2023: € 187,686 ▲ 22% vs 2022 (€ 153,391) Favourable step	€ 118,986 Cash 2024: € 118,986 ▼ 37% vs 2023 (€ 187,686) Unfavourable step	€ 108,459 Cash 2025: € 108,459 ▼ 9% vs 2024 (€ 118,986) Unfavourable step	▼ 9%
Retained profit	€ 118,713 Retained profit 2022: € 118,713 First fiscal year in the series	€ 150,963 Retained profit 2023: € 150,963 ▲ 27% vs 2022 (€ 118,713) Favourable step	€ 163,438 Retained profit 2024: € 163,438 ▲ 8% vs 2023 (€ 150,963) Favourable step	€ 191,551 Retained profit 2025: € 191,551 ▲ 17% vs 2024 (€ 163,438) Favourable step	▲ 17%
Bank debt	€ 316,576 Bank debt 2022: € 316,576 First fiscal year in the series	€ 246,346 Bank debt 2023: € 246,346 ▼ 22% vs 2022 (€ 316,576) Favourable step	€ 230,981 Bank debt 2024: € 230,981 ▼ 6% vs 2023 (€ 246,346) Favourable step	€ 142,106 Bank debt 2025: € 142,106 ▼ 38% vs 2024 (€ 230,981) Favourable step	▼ 38%
Balance sheet total	€ 775,262 Balance sheet total 2022: € 775,262 First fiscal year in the series	€ 847,696 Balance sheet total 2023: € 847,696 ▲ 9% vs 2022 (€ 775,262) Unchanged	€ 703,875 Balance sheet total 2024: € 703,875 ▼ 17% vs 2023 (€ 847,696) Unchanged	€ 839,146 Balance sheet total 2025: € 839,146 ▲ 19% vs 2024 (€ 703,875) Unchanged	▲ 19%
Employees (FTE)	0.5 Employees (FTE) 2022: 0.5 First fiscal year in the series	0.5 Employees (FTE) 2023: 0.5 Unchanged (0.5) Unchanged	0.5 Employees (FTE) 2024: 0.5 Unchanged (0.5) Unchanged	0.5 Employees (FTE) 2025: 0.5 Unchanged (0.5) Unchanged

Key figures of ARSPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to ARSPHARMA?

What happened at ARSPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 29, 2026 New annual accounts for financial year 2025: profit of € 28,113 (▲ 125% vs 2024). Source: NBB ↗
Oct 12, 2012 New establishment in Malle. KBO
Oct 12, 2012 Start of the company according to the CBE. KBO

In short

From € 1,118 loss in 2022 to € 28,113 profit in 2025.

Paid € 53,001 in corporate taxes since 2022.

Best year ever: 2023, with € 32,250 profit.

Original PDFs at the National Bank ↗

A new publication or filing at ARSPHARMA? We notify you, reason included.

Follow ARSPHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Antwerpsesteenweg 281A

2390 Malle

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS arspharma.be

Technologies

AWS S3Cookie ConsentFacebook PixelGoogle FontsGoogle Tag ManagerMailchimpNginxPHPWPMLWooCommerceWordPressYoast SEOjQuerylazysizes

Hosting & Email

Email provider

Microsoft 365

Hosting

COMBELL-AS, BE

Website info

HTTPS Ja

Languages FR, NL

Features

Webshop Newsletter Ads Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

Details

Company number

0849.745.437

VAT number

BE 0849.745.437

Registered office

Antwerpsesteenweg 281A, 2390 Malle

Names & denominations

ARSPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

12 October 2012

Peppol

Active · Active since 27 May 2025

Contact

arspharma.be

Activities · NACE

Activiteiten van interieurarchitecten

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗